SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors, rather than a peptide. Understanding how it was used in research starts with the original papers' study methods.
The original exercise-capacity paper
Billon and colleagues' ACS Chemical Biology paper examined receptor activity, cellular respiration and mouse exercise capacity. Its pharmacokinetic experiment used intraperitoneal administration at 30 mg/kg. Other mouse experiments used 50 mg/kg twice daily. These were distinct experiments, rather than a single subcutaneous schedule.
The metabolic-syndrome paper
The subsequent metabolic-syndrome study used intraperitoneal administration at 50 mg/kg twice daily in defined mouse models. Its methods identify the population and duration for each experiment. The study was not a comparison of human injection schedules.
How to read the administration methods
| Method field | Question it answers |
|---|---|
| Compound identity | Which chemical was studied? |
| Vehicle | Which experimental formulation carried it? |
| Route | How was the formulation administered? |
| Amount and frequency | What exposure was tested? |
| Model and endpoint | Which outcome was measured in which population? |
Why a peptide mixing recipe does not answer this question
Grouping products under a "peptide" catalog does not change their chemical identity. Formulation methods concern the exact compound and experimental vehicle. The original paper's route and formulation need to stay attached to its results.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →What "exercise mimetic" describes
The term describes experimental responses associated with exercise, such as gene-expression changes and measured endurance in mice. It does not make every exercise outcome interchangeable with a drug-study endpoint. Each claim needs its matching measured result.
FAQ
Was the original work a Nature Communications human trial?
No. The original exercise-capacity paper was published in ACS Chemical Biology and included cell and mouse experiments.
Does "30 mg/kg" describe the whole study?
No. It identifies an experiment-specific amount. The paper separately describes repeated-administration experiments.
What should a useful study summary preserve?
The compound, vehicle, route, amount, frequency, model, duration and endpoint, rather than a schedule detached from its methods.
Related evidence guide
Browse the peptide research hub
Footer Disclaimers
Platform: FormBlends is an informational platform. Nothing on this page constitutes medical advice, a prescription, or a treatment recommendation. Consult a licensed healthcare provider before using any compound discussed here.
Research Compound: SLU-PP-332 is a research compound. It is not approved by the FDA or any equivalent regulatory agency for human therapeutic or diagnostic use. It is not a dietary supplement. It is intended for in-vitro and animal research use only by qualified investigators operating within applicable institutional and legal frameworks.
Results: Animal study outcomes described on this page have not been replicated in human clinical trials. Individual results, if any, may vary. No outcome claims are made for human use.
Trademark: "SLU-PP-332" refers to a research compound associated with St. Louis University. FormBlends has no affiliation with St. Louis University. All trademarks and institutional names are the property of their respective owners.
Do not accept a COA for injectable use that lacks LAL or equivalent endotoxin data.
Do not use water alone.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →